3-tert-butyl-N,1-dimethylpyrazol-5-amine | 1161364-22-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-tert-butyl-N,1-dimethylpyrazol-5-amine
• 英文别名: 5-tert-butyl-N,2-dimethylpyrazol-3-amine
• CAS: 1161364-22-2
• 化学式: C₉H₁₇N₃
• 分子量: 167.254
• InChiKey: PKKUWEVLNNJSHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-(3-tert-butyl-1-methylpyrazol-5-yl)-2,2,2-trifluoro-N-methylacetamide 在 氨 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以100%的产率得到3-tert-butyl-N,1-dimethylpyrazol-5-amine
  参考文献：
  名称：

  [EN] INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA
  [FR] INHIBITEURS DE LA FORMATION DE BIOFILMS DE BACTÉRIES GRAM POSITIF ET GRAM NÉGATIF

  摘要：

  公开号：

  WO2009077844A3

文献信息

• Amide Compound
  申请人：Matsumoto Takahiro

  公开号：US20080312226A1

  公开（公告）日：2008-12-18

  There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I 0 ): R 1 —C—R 2 —R 3 —R 4 (I 0 ) wherein Z is oxygen or sulfur; R 1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R 1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R 2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R 3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, —CO—, etc.; and R 4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

  提供了一种FAAH抑制剂和预防或治疗脑血管疾病或睡眠障碍的药物，其中预防或治疗剂包括化合物(I0)的一种：R1-C-R2-R3-R4(I0)，其中Z为氧或硫；R1为芳基，可以被取代，或者是可以被取代的杂环基；R1a为氢原子，可以被取代的碳氢基，羟基等；R2为可以被取代的哌啶-1,4-二基，或者可以被取代的哌嗪-1,4-二基；R3为从具有1到3个氮、氧和硫杂原子的5元芳香杂环基中消除两个氢原子形成的基团，可以进一步被取代，-CO-等；R4为可以被取代的碳氢基或者可以被取代的杂环基；或其盐。
• INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA
  申请人：Ammendola Aldo

  公开号：US20090192192A1

  公开（公告）日：2009-07-30

  The present invention relates to the use of compounds as broad spectrum inhibitors of bacterial biofilm formation. In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative and Gram-positive bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of bacterial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.

  本发明涉及使用化合物作为广谱细菌生物膜形成的抑制剂。具体而言，本发明涉及一系列化合物，能够阻断革兰氏阴性和革兰氏阳性细菌的群体感应系统，一种制造它们的方法，含有它们的制药组合物以及它们用于治疗和预防细菌损害和疾病的用途，特别是对于需要抑制病原体的群体感应调节表型的疾病有优势的情况。
• UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
  申请人：Ancureall Pharmaceutical (Shanghai) Co., Ltd.

  公开号：EP3424924A1

  公开（公告）日：2019-01-09

  Provided are a urea compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof as an FLT3 tyrosine protein kinase inhibitor, particularly in the prevention and/or treating of cancer.

  本发明提供了通式（I）代表的脲化合物、其药学上可接受的盐、其制备方法，以及其作为FLT3酪氨酸蛋白激酶抑制剂的用途，特别是在预防和/或治疗癌症中的用途。
• SUBSTITUIERTE CYCLISCHE CARBOXAMID- UND HARNSTOFF-DERIVATE ALS LIGANDEN DES VANILLOID-REZEPTORS
  申请人：Grünenthal GmbH

  公开号：EP2606033A1

  公开（公告）日：2013-06-26
• NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS
  申请人：Wu Tongfei

  公开号：US20120135981A1

  公开（公告）日：2012-05-31

  The present invention is concerned with novel substituted triazole and imidazole derivatives of Formula (I) wherein R 1 , R 2 , A 1 , A 2 , A 3 , A 4 , X, and Het 1 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.